An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer.
Latest Information Update: 28 Nov 2022
Price :
$35 *
At a glance
- Drugs E 7820 (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Eisai Inc
- 01 Nov 2022 Status changed from completed to discontinued.
- 25 Aug 2017 Status changed from active, no longer recruiting to completed.
- 29 Apr 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.